[{"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Viral mutation update", "description": "Covid-19: New coronavirus variant is identified in UK\n\nhttps://www.bmj.com\n\nhttps://www.bmj.com/content/371/bmj.m4857\n\nDriving infections in the south east\n\nWhat do we know?\n\nVUI-202012/01\n\nVariant Under Investigation\n\nDefined by a set of 17 mutations\n\nMost significant is an N501Y mutation\n\nSpike protein\n\nMore infectious\n\nHow was the variant detected?\n\nGenomics UK\n\nPublic health agencies, Wellcome Sanger Institute, 12 academic institutions\n\nRandom genetic sequencing of positive samples around the UK\n\nSet up in April 2020, sequenced 140,000 virus genomes\n\nUses the data to track outbreaks, identify variant viruses, publish old weekly report \n\nhttps://www.cogconsortium.uk/data/\n\nHow common is it?\n\nAs of 13 December\n\n1,108, 60 different local authorities\n\nSunday, 20th 60% of new cases in London\n\nSouth east of England, Scotland\n\nSeeded every part of Wales\n\nNetherlands, Italy, Austria, Belgium flight ban, Eurostar to Belgium\n\nFrance and Germany expected soon\n\nFirst spotted in late September\n\nNow 20% of viruses sequenced in Norfolk\n\nEssex 10%\n\nSuffolk 3%\n\nNo data to suggest it\u2019s imported\n\nDoes this variant spread more quickly?\n\nInitially it was a correlation\n\nUp to 70% more infectious\n\nRaising R value by 0.4\n\nIs the new variant more dangerous?\n\nPorton Down\n\nWill the vaccine still work?\n\nMay have an effect on neutralising antibodies", "link": "https://www.youtube.com/watch?v=MINIibH2Iaw", "date_published": "2020-12-20 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}, {"source": "https://www.youtube.com/feeds/videos.xml?channel_id=UCF9IOB2TExg3QIBupFtBDxg", "title": "Excellent vaccine news", "description": "Pfizer progress\n\n400 GPs, 83 hospitals\n\nHalf a million so far\n\n200,000 a day should be receiving jabs, well over one million a week by Christmas\n\nPfizer orders\n\n50 million doses by end of 2020\n\nUS, 100 \u2013 500 million doses\n\nEU, 200 million doses\n\nUK, 40 million doses\n\nEMA, Monday 21st December\n\nModerna\n\nFDA grants emergency approval\n\nSix million doses ready to go\n\nThe end begins just after Christmas\n\nApproved within days of Christmas\n\nSenior Whitehall sources\n\nMedicines and Healthcare Regulatory Agency (MHRA)\n\n28 or 29 December\n\nFinal data provided to the regulator on Monday 21st December\n\nFour million doses ready\n\nFootball stadia, racecourses, conference centres, pharmacies\n\nFirst week of January\n\nSeveral million doses a week\n\nUK, 100 million doses (80 million produced in UK)\n\nIndia, 50 million doses in stock\n\nFirst batch of four million doses, Netherlands and Germany\n\nAstraZeneca has 15 million doses of active ingredients ready, filled into vials in days\n\nTwo doses, 4 week gap\n\nLeaving an adequate gap between doses is the most crucial way to boost efficacy\n\nOxford AstraZeneca orders\n\nEU, 400 million doses\n\nUK, 100 million\n\nUS, 300 million\n\nChina, 200 million\n\nJapan, 120 million\n\nBrazil, 100 million\n\nIndonesia, 100 million\n\nAustralia, 33.6 million\n\nEgypt 30 million\n\nArgentina 32 million\n\nCanada 20 million\n\nArgentina and Mexico to produce for Latin America\n\nVaccines alliance for poorer countries, 300 million\n\nThree billion does in 2021\n\nPhase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses, (Nature Medicine, 17th December)\n\nViral vector coronavirus vaccine, ChAdOx1 nCoV-19 (AZD1222)\n\nhttps://www.nature.com/articles/s41591-020-01179-4\n\n190 vaccines currently in development\n\nNeutralizing antibodies against the viral spike protein correlate with protection\n\nAdditional antibody functions may also be important in preventing infection\n\nTwo jabs, 56 days apart\n\nSD/SD  n\u2009=\u200920\n\nSD/LD n\u2009=\u200932\n\nA booster dose is safe and better tolerated than priming doses\n\nAfter second dose\n\nIncreased anti-spike neutralizing antibody titers,\n\nIncreased cell mediated immunity\n\nIncreased neutrophil and monocyte phagocytosis\n\nIncreased complement activation\n\nIncreased natural killer cell activation\n\nSD / SD\n\nStronger antibody responses\n\nT cell responses did not increase with either booster dose\n\nThese data support the two-dose vaccine regime that is now being evaluated in phase 3 clinical trials", "link": "https://www.youtube.com/watch?v=NGQKAvsnISg", "date_published": "2020-12-19 00:00:00+00:00", "persistent": false, "user": null, "language": "en-US"}]